drugset / Trial / NCT07244341
A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will assess the safety and tolerability of valemetostat in combination with darolutamide in participants with Metastatic Castration Resistant Prostate Cancer (mCRPC).
Timeline
- Start
- 2025-12-03
- Primary completion
- 2028-01-31
- Completion
- 2029-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Valemetostat | Small molecule | — | — |
| Background | Darolutamide | Other / unclassified | — | — |